Clinical Candidate Developed Articles & Analysis
68 articles found
For centuries outbreaks of numerous diseases called pandemics would plague human populations in large regions or even world-wide. Throughout history there have been a number of widespread pandemics the most devastating being the Black Death pandemic that killed over 75 million people in the 1350’s and the latest being influenza outbreaks, also known as the Spanish flu, in 1918 and ...
Preclinical drug discovery represents a critical phase in the development of new therapeutics. It is the process that bridges the gap between basic research and clinical testing, allowing for the evaluation of potential drug candidates in biological systems before they are tested in humans. ...
One of the primary uses is in drug testing and development. Researchers utilize these cell lines to screen potential therapeutic agents, examining their effectiveness in inhibiting cancer cell growth. This screening process helps identify promising candidates for further development into clinical treatments. In addition to drug ...
Recombinant protein drugs refer to protein products that originate from animals and plants and are developed through biotechnology research. These protein drugs exhibit certain biological activity and can prevent, diagnose, and treat diseases in humans, animals, and plants. Compared with small molecular drugs, recombinant protein drugs offer advantages such as high activity, high specificity, and ...
What Is PROTAC Technology? Proteolytic targeting chimera (PROTAC) is a new type of drug design technology that works by inducing the degradation of target proteins. Unlike conventional small molecules that typically inhibit protein function, PROTACs facilitate the ubiquitination and subsequent degradation of specific proteins. This bifunctional molecule consists of two distinct elements: a ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and ...
When we talk about antibody sequencing, we often think of issues related to disease treatment and improving human health. Nanobody sequencing provides us with a more precise and efficient solution. Nanobodies, also known as single-domain antibodies, are antibodies composed of a single functional domain. They have the advantages of small size, high stability, and good penetration, and therefore ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Coupling drugs combine the precise targeting and potent killing properties, has become a widely recognized form of medication in recent years. Radioactive drug conjugates (RDCs), as a particular form of coupling drugs, are formed by combining radioactive isotopes with disease-targeting molecules. According to the application of RDCs, they can be divided into two main categories: diagnostic RDCs ...
What is a Nanobody?Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. However, nanobodies have higher solubility and stability, and have unique advantages in ...
Therefore, there is a need to deepen our understanding of the physical, chemical, and biological properties of these adjuvants to provide a theoretical basis for determining the quality attributes of each adjuvant and selecting the appropriate type of adjuvant as early as possible in the clinical development phase. Type of Aluminum Adjuvants The two main types of ...
Abstract Background: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality, most of which occurs in low and middle-income countries. The accurate and timely diagnosis of preeclampsia is critical in management of affected pregnancies to reduce maternal and fetal/neonatal morbidity and mortality, yet difficulties remain in establishing the rigorous ...
The opioid crisis in the United States is a devastating public health issue, with over 70,000 overdose deaths annually, largely driven by the highly potent synthetic opioid fentanyl. The urgency to address this crisis has spurred the development of innovative therapies to prevent and reverse fentanyl overdoses. In this blog, we will explore the groundbreaking preclinical work on CSX-1004, a fully ...
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. ...
By profiling patient samples using scRNA-seq, researchers can identify cell types that are relevant to the disease and develop more accurate disease models. These models can be used to study disease progression, test drug candidates, and gain insights into drug mechanisms of action. In the clinical development phase, ...
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. ...
Relevance of scRNA-seq in Drug Development In drug development, scRNA-seq plays a crucial role in selecting relevant preclinical disease models. ...
Ultromics will be sharing its groundbreaking AI research and innovation at the American Society of Echocardiography’s annual Scientific Sessions. ASE’s Foundations and the Future of Cardiovascular Ultrasound sessions bring together echo professionals and enthusiasts from across forty-five countries with a selection of networking events, seminars, and workshops from the top minds in ...
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
Preliminary results of a large-scale study demonstrating the clinical benefits of EchoGo® Heart Failure were shared at the American College of Cardiology (ACC 2023) conference last month. Using only an apical four-chamber ultrasound view, this new AI-enabled platform can identify heart failure with preserved ejection fraction (HFpEF) and has been shown to minimize the indeterminate ...